Two synthetic GHRPs that have received much attention in biochemical studies are Tesamorelin and Ipamorelin. Both Tesamorelin and Ipamorelin have been speculated to have the capacity to increase GH secretion by activating the ghrelin receptor. The peculiar impact of these peptides has piqued the curiosity of the scientific community, leading to a plethora of studies aiming at elucidating their molecular processes and prospective effects.
Tesamorelin’s potential properties have been studied mostly within the context of metabolic diseases and, more specifically, HIV-associated lipodystrophy. Ipamorelin, on the other hand, has suggested promise in a larger variety of studies, such as those examining its effects on obesity and growth.
This introductory exposition delves into the science behind Tesamorelin and Ipamorelin, highlights their potential synergy, and emphasizes the need for more exploratory study into the pharmacological effects of the two.
Tesamorelin, or growth hormone-releasing peptide (GHRP), is a synthetic peptide having a well-defined amino acid sequence. It comprises a chain of 44 amino acids and seems to work by inducing pituitary secretion of growth hormone (GH).
Tesamorelin’s possible impact within the context of certain diseases, including HIV-associated lipodystrophy and age-related GH decrease, has been investigated. Although further research is required to definitively evaluate its potential, its hypothesized capacity to increase GH secretion makes it a topic of study in the context of various health-related conditions.
Mod GRF (1-29) Peptide
MOD GRF (1-29) is a GHRH analog synthesized in a lab. It was first produced in the 1980s when research suggested that the first 29 amino acids of GHRH may have had all the biological functions normally attributed to the full-length 44-residue protein. The original peptide, GRF (1-29), seems to have all the qualities of the full-length hormone despite being the smallest section of GHRH. Sermorelin, also known as GRF 1-29, is another shortened synthetic version of GHRH with the same number of amino acids. Four substituted amino groups extend the amino acid chains of modified GRF (1-29).
Synthetic peptide Ipamorelin is a member of the growth hormone-releasing peptide (GHRP) family. Alanine, glutamine, histidine, leucine, and arginine are the five amino acids that make up its chemical structure.
The sequence in question seems to provide Ipamorelin, a potentially powerful GH secretagogue, the capacity to increase growth hormone (GH) release by activating the ghrelin receptor. Research suggests that Ipamorelin stands out among GHRPs because it seems to have selective activity with low influence on other hormones, making it a promising research subject for studying how GH is controlled.
Tesamorelin, Mod GRF, and Ipamorelin Peptide Blend: Growth Hormone
Tesamorelin and Ipamorelin seem to have a synergistic impact in the setting of growth hormone insufficiency due to their complex action method.
Researchers have hypothesized that a combination of Tesamorelin and Ipamorelin, given simultaneously, may have a multiplicative impact. Ipamorelin seems to directly stimulate GHSR, while Tesamorelin appears to activate GHRH receptors, both leading to enhanced GH secretion. It is thought that this synergistic effect may enhance GH response as a whole, which may aid things like body composition, lipid profiles, insulin sensitivity, and metabolic function.
Findings imply that Tesamorelin and Ipamorelin may improve pituitary gland activity that eventually enhances the release of endogenous growth hormone by targeting separate components of the growth hormone axis via their respective methods.
Tesamorelin, Mod GRF, and Ipamorelin Peptide Blend: Lipodystrophy
In addition to insulin resistance, dyslipidemia, and an increased risk of cardiovascular problems, lipodystrophy is often seen. Experimental studies have suggested that exposure to Tesamorelin to research models of lipodystrophy may improve insulin sensitivity and lipid profiles and may cause a significant loss of visceral adipose tissue (VAT).
Investigations purport that Tesamorelin may promote endogenous growth hormone production and facilitate lipolysis by activating the growth hormone-releasing hormone receptor (GHRHR). Therefore, Tesamorelin may aid in preserving abdominal subcutaneous adipose tissue and bringing about positive changes in lipid metabolism.
Also, Ipamorelin has suggested promise in studies investigating its impact on adipose tissue metabolism. Synergistic impact, which may further amplify the decrease of VAT and improve metabolic parameters in models of lipodystrophy, is postulated about the combined use of Tesamorelin and Ipamorelin.
Tesamorelin, Mod GRF, and Ipamorelin Peptide Blend: Cognition
An ever-expanding body of research suggests that growth hormone and its secretagogues, such as Tesamorelin and Ipamorelin, may have a modulatory impact on neuroplasticity, neuronal survival, and synaptic plasticity, all of which are critical for peak cognitive performance. Tesamorelin has been speculated to improve memory and learning in animal models, presumably via neurogenesis and synaptic plasticity.
Simultaneously, Ipamorelin suggests promise in improving spatial memory and cognition in experimental animal models. There is speculation that the synergistic mechanisms of action between Tesamorelin and Ipamorelin may increase the cognitive properties of their combined presentation. However, further research is required to confirm these results and clarify the biological effects of the mix on cognitive performance.
Tesamorelin, Mod GRF, and Ipamorelin Peptide Blend: Type 2 Diabetes
Positive results from preliminary studies have piqued researchers’ interest in combining Tesamorelin and Ipamorelin in the context of Type 2 Diabetes Mellitus (T2DM). Scientists hypothesize that both peptides suggest promise in improving glycemic management and reducing metabolic abnormalities related to type 2 diabetes.
Research suggests that improvements in insulin sensitivity and glucose utilization may result from Tesamorelin’s activity by increasing endogenous growth hormone release. Additionally, it has been purported that Ipamorelin may affect glucose metabolism and insulin sensitivity. Tesamorelin and Ipamorelin may have synergistic effects when combined, including improvements in insulin sensitivity and decreased visceral adiposity in the context of type 2 diabetes, as speculated by professionals.
Tesamorelin & Mod GRF & Ipamorelin blend for sale is available at Core Peptides.
[i] Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. PMID: 21668043. https://pubmed.ncbi.nlm.nih.gov/21668043/
[ii] Gao Y, Yuan X, Zhu Z, Wang D, Liu Q, Gu W. Research and prospect of peptides for use in obesity treatment (Review). Exp Ther Med. 2020 Dec;20(6):234. doi: 10.3892/etm.2020.9364. Epub 2020 Oct 16. PMID: 33149788; PMCID: PMC7604735. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604735/
[iii] National Center for Biotechnology Information (2023). PubChem Compound Summary for , Tesamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin.
[iv] National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
[v] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/